Login / Signup

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Robert N A KnoblerM Geroldinger-SimićA KreuterN HunzelmannPia MoinzadehFranco RongiolettiChristopher P DentonL MouthonM CutoloV SmithA GabrielliMartine BagotA B OlesenI FoeldvariAhmad JaliliV KähäriS KárpátiK KofoedM OlszewskaJ PaneliusPietro QuaglinoJulien SeneschalM SticherlingC SunderkötterAdrian TanewP WolfM WormA SkrokLidia RudnickaT Krieg
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes.
Keyphrases
  • systemic sclerosis
  • interstitial lung disease
  • soft tissue
  • wound healing
  • clinical practice
  • palliative care
  • preterm infants
  • mesenchymal stem cells
  • bone marrow
  • cell therapy